Oral secondary treatment was found to improve advanced cases in trials.
The Food and Drug Administration (FDA) approved Mirai Therapeutic’s drug adagrasib for use in advanced lung cancer cases on Monday. The oral drug is designed to target KRAS, a mutated gene that occurs in 13% of non-small cell lung cancers, the most common iteration of lung cancer. It is intended as a secondary treatment.
The FDA announced, “Approval was based on KRYSTAL-1, a multicenter, single-arm, open-label clinical trial (NCT03785249) which included patients with locally advanced or metastatic NSCLC with KRAS G12C mutations. Efficacy was evaluated in 112 patients whose disease has progressed on or after platinum-based chemotherapy and an immune checkpoint inhibitor, given either concurrently or sequentially.“
As the Lord Leads, Pray with Us…
- For FDA Commissioner Robert Califf to seek God’s direction as he heads the agency.
- For FDA researchers and scientists as they run trials and assess data.
- For U.S. health officials to be wise in their prescribing of drugs for illnesses and medical conditions.
Sources: Food and Drug Administration, Reuters
